Published in Lancet on September 02, 1967
Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci U S A (1974) 4.10
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J (1974) 3.80
The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest (1968) 3.66
The effect of acetylsalicyclic acid on platelet function. J Exp Med (1968) 2.35
Structural changes in human serum albumin induced by ingestion of acetylsalicylic acid. J Clin Invest (1969) 1.75
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry (2010) 1.55
The discovery of aspirin's antithrombotic effects. Tex Heart Inst J (2007) 1.45
The effectiveness of low dose slow release aspirin as an antiplatelet agent. J R Soc Med (1993) 1.40
Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction. J Pharm Health Care Sci (2017) 1.39
Inhibition by aspirin of release of antiheparin activity from human platelets. Br Med J (1969) 1.25
Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med (1989) 1.24
Secondary prevention of myocardial infarction--the present state of the ART. Br Med J (1980) 1.16
Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol (2009) 1.10
Effect of some inhibitors of platelet aggregation on platelet nucleotides. Biochem J (1969) 1.08
Historical perspective and future directions in platelet research. J Thromb Haemost (2011) 1.06
Aspirin all round? Br Med J (Clin Res Ed) (1988) 1.04
Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol (2008) 1.04
Effects of normal and aspirin platelets on defective secondary aggregation in the Hermansky-Pudlak syndrome. A test for storage pool deficient platelets. Am J Pathol (1972) 1.00
Aspirin-induced prolongation of the ivy bleeding time. Its diagnostic usefulness. Calif Med (1971) 0.99
Prophylactic ASA against Myocardial Infarction: Physician Attitudes and Practices. Can Fam Physician (1991) 0.99
Effects of collagen and of aspirin on the concentration of guanosine 3':5'-cyclic monophosphate in human blood platelets: measurement by a prelabelling technique. Biochem J (1974) 0.99
Antiplatelet drugs. Br J Pharmacol (2006) 0.98
Aspirin and gastrointestinal bleeding. An opinion. Calif Med (1969) 0.96
Ultrastructural study of the effect of aspirin on in vitro platelet-collagen interaction and platelet adhesion to injured intima in the rabbit. Am J Pathol (1970) 0.95
Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgrad Med J (1990) 0.91
Prostaglandins in vascular disease: a seminal approach. Br Med J (Clin Res Ed) (1981) 0.90
The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia. Clin Interv Aging (2013) 0.87
Regular aspirin intake and acute myocardial infarction. Br Med J (1974) 0.87
The first randomized trial of aspirin for heart attack and the advent of systematic overviews of trials. J R Soc Med (2006) 0.85
Platelet aggregation and the platelet release reaction in thromboembolism. Can Med Assoc J (1970) 0.84
Dipyridamole and aspirin tested against an experimental model of thrombosis. Ann Surg (1973) 0.84
Thrombosis prevention by acetylsalicylic acid in hyperlipemic rats. Can Med Assoc J (1970) 0.82
The influence of salicylate on platelets and whole blood adenine nucleotides. Br J Pharmacol (1969) 0.81
Platelets, aspirin, and cardiovascular disease. Postgrad Med J (1998) 0.80
Gel-filtered human platelets. Ultrastructure, function, and role of proteins in inhibition of aggregation by aspirin. Am J Pathol (1976) 0.79
Aspirin delimits platelet life span by proteasomal inhibition. PLoS One (2014) 0.78
Aspirin decreases platelet uptake on Dacron vascular grafts in baboons. Ann Surg (1984) 0.78
Aggregation of equine platelets by Onchocerca cervicalis collagen. Am J Pathol (1983) 0.78
Aspirin for reducing cancer metastases? J Natl Med Assoc (1977) 0.77
Light on platelets. J Physiol (2005) 0.77
Inhibition of primary ADP-induced platelet aggregation in normal subjects after administration of nitrofurantoin (furadantin). J Clin Invest (1973) 0.76
Platelet disorders: a review of disturbances in adhesion, aggregation, and release reaction. Calif Med (1972) 0.76
The effect of aspirin on rebleeding in traumatic hyphema. Trans Am Ophthalmol Soc (1976) 0.76
Aspirin in dermatology: Revisited. Indian Dermatol Online J (2016) 0.75
Use of antiplatelet inhibitors in peripheral vascular interventions. Semin Intervent Radiol (2005) 0.75
Dollars: prophylaxis or cure? J Natl Med Assoc (1979) 0.75
Strokes, transient ischemic attacks and asymptomatic bruits. West J Med (1979) 0.75
Sudden death. Br Med J (1979) 0.75
Anaesthetics and platelets. Br Med J (1971) 0.75
Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Br J Pharmacol (1981) 0.75
Platelet aggregation by rat liver: need for tissue and plasma factors. Am J Pathol (1971) 0.75
Theory and practice in prevention of arterial thrombosis. Br Heart J (1982) 0.75
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood (1996) 7.31
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest (1968) 3.66
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA (1996) 3.50
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet (1993) 3.03
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest (1973) 2.94
Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood (1991) 2.92
Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest (1973) 2.71
Decreased adhesion of platelets to subendothelium in von Willebrand's disease. J Lab Clin Med (1974) 2.44
Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med (1975) 2.31
Studies of the release from human platelets of the growth factor for cultured human arterial smooth muscle cells. Circ Res (1978) 2.14
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med (1990) 2.05
Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med (1991) 1.91
Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med (1974) 1.86
Transient arthritis after rubella vaccination. Am J Dis Child (1969) 1.86
Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest (1977) 1.85
Platelet physiology and abnormalities of platelet function (second of two parts). N Engl J Med (1975) 1.69
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem (1989) 1.63
Separation of sub-units of antihemophilic factor (AHF) by agarose gel chromatography. Thromb Diath Haemorrh (1972) 1.61
Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation. Br J Haematol (1970) 1.57
Secretable storage pools in platelets. Annu Rev Med (1979) 1.49
Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science (1973) 1.49
Aspirin--a dangerous drug? JAMA (1974) 1.47
Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol (2000) 1.47
Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate--dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med (1978) 1.46
Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med (1971) 1.46
Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood (1978) 1.39
Thrombogenic factors and recurrent coronary events. Circulation (1999) 1.38
Immune tolerance in hemophiliacs: can we afford it? Is it worth it? Baxter Previously Untreated Patient Study Group. Transfusion (1999) 1.38
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Ionic effects on firefly bioluminescence assay of red blood cell ATP. Anal Biochem (1966) 1.33
Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood (1979) 1.33
The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia (2004) 1.26
Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med (1982) 1.26
Correction of the platelet abnormality in von Willebrand's disease by cryoprecipitate. Am J Med (1972) 1.25
Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia. J Lab Clin Med (1968) 1.24
Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol (1970) 1.23
Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia--"storage pool disease". Blood (1972) 1.23
Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood (1986) 1.21
Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. J Clin Invest (1984) 1.20
A familialdefect in platelet function associated with imapired release of adenosine diphosphate. N Engl J Med (1969) 1.18
Platelet membrane glycoproteins in thrombasthenia, Bernard-Soulier syndrome, and storage pool disease. J Lab Clin Med (1979) 1.17
A congenital defect in platelet prostaglandin production associated with impaired hemostasis in storage pool disease. Prostaglandins (1973) 1.17
Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (platelet factor 3 deficiency). A comparison with Glanzmann's thrombasthenia and von Willebrand's disease. Am J Med (1967) 1.16
Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Lancet (1994) 1.16
Isolated deficiency of platelet procoagulant activity. Am J Med (1979) 1.15
Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood (1997) 1.14
HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr (1994) 1.14
Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia (1998) 1.13
Red blood cells: their dual role in thrombus formation. Science (1980) 1.13
Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest (1986) 1.13
Thrombocytopathia due to abnormalities in platelet release reaction--studies on six unrelated patients. Blood (1972) 1.12
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood (1995) 1.11
Choice of replacement therapy for hemophilia. J Thromb Haemost (2003) 1.08
Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost (1981) 1.07
Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia. Blood (1993) 1.06
Editorial: Platelet function tests and their interpretation. J Lab Clin Med (1976) 1.06
Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J Lab Clin Med (1983) 1.06
Von Willebrand's disease--diagnostic criteria. Blood (1968) 1.06
Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr (1999) 1.05
Inhibition of sulfhydryl-dependent platelet functions by penetrating and non-penetrating analogues of parachloromercuribenzene. Blood (1968) 1.05
Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood (1985) 1.05
Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost (2010) 1.04
Studies of platelet 5-hydroxytryptamine (serotonin) in storage pool disease and albinism. J Clin Invest (1974) 1.03
Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. Am J Epidemiol (1985) 1.03
Antiplatelet therapy (first of two parts). N Engl J Med (1978) 1.02
Content and thrombin-induced release of acid hydrolases in gel-filtered platelets from patients with storage pool disease. Blood (1975) 1.02
Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group. N Engl J Med (1993) 1.02
Properties of the platelet retention (von Willebrand) factor and its similarity to the antihemophilic factor (AHF). Blood (1973) 1.01
A study of liver biopsies and liver disease among hemophiliacs. Blood (1985) 1.00
Thromboembolism--a continuing challenge. N Engl J Med (1970) 0.97
Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood (1985) 0.97
Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med (1991) 0.96
The effect of shear rate on platelet interaction with subendothelium exposed to citrated human blood. Microvasc Res (1980) 0.96
Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA (1992) 0.95
Release of human platelet factor V activity is induced by both collagen and ADP and is inhibited by aspirin. Blood (1980) 0.95
Decreased platelet adhesion on vessel segments in von Willebrand's disease: a defect in initial platelet attachment. J Lab Clin Med (1983) 0.95
The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med (1989) 0.94
Ultrastructural findings in storage pool disease and aspirin-like defects of platelets. Am J Pathol (1973) 0.94
Impaired interaction (adhesion-aggregation) of platelets with the subendothelium in storage-pool disease and after aspirin ingestion. A comparison with von Willebrand's disease. N Engl J Med (1975) 0.94
The effect of clinical dextran on platelet aggregation, adhesion, and ADP release in man: in vivo and in vitro studies. J Lab Clin Med (1967) 0.94
Abnormalities of platelet function in patients with polycythemia vera. Cancer Res (1973) 0.93
Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII. J Thromb Haemost (2011) 0.93
Platelet interaction with collagen fibrils in flowing blood. II. Impaired adhesion-aggregation in bleeding disorders. A comparison with subendothelium. Thromb Haemost (1977) 0.93
Coagulopathy of fulminant hepatic failure. Semin Liver Dis (1986) 0.93
Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest (1994) 0.92
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis. Am Heart J (1976) 0.90
Phylogenetic studies with pemphigus and pemphigoid antibodies. Acta Derm Venereol (1978) 0.90
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia (2004) 0.90
Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency--a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor. Thromb Haemost (1997) 0.89
Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood (1998) 0.89
Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. II. Relationships among platelet adhesion, thrombus dimensions, and fibrin formation. J Lab Clin Med (1980) 0.89
Use of edrophonium (tensilon) in the evaluation of supraventricular tachycardias. Am J Cardiol (1966) 0.89
Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia. Blood (1985) 0.88